23 Jul 2013 07:00
Akers Biosciences, Inc.
("ABI" or the "Company")
Director's Dealing
Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that on 22 July 2013 Raymond F. Akers Jr., Ph.D., Executive Chairman of the Board, has disposed of 7,000,000 common shares of no par value in the Company ("Shares").
In 2007, Dr Akers borrowed $655,000 in order to acquire shares in the Company when the share price was 40p. Dr Akers has now agreed to settle the outstanding amount through this transfer of 7 million Shares.
Following the transaction, Dr Akers retains an interest in 1,824,338 Shares, representing approximately 0.7 per cent of the Company's common stock and approximately 0.6 per cent of the Company's voting capital.
Enquiries:
Thomas A. Nicolette, President and CEO
| Tel. +1 856 848 8698 |
Antony Legge / James Thomas Daniel Stewart (Nomad and Broker)
| Tel. +44 (0)20 7776 6550 |
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.